Tumors recruit mesenchymal stem cells (MSCs) to facilitate healing, which induces their conversion into cancer-associated fibroblasts that facilitate metastasis. However, this process is poorly understood on the molecular level. Here we show that the CXCR6 ligand CXCL16 facilitates MSC or Very Small Embryonic-Like (VSEL) cells recruitment into prostate tumors. CXCR6 signaling stimulates the conversion of MSCs into cancer-associated fibroblasts, which secrete stromal-derived factor-1, also known as CXCL12. CXCL12 expressed by cancerassociated fibroblasts then binds to CXCR4 on tumor cells and induces an epithelial to mesenchymal transition, which ultimately promotes metastasis to secondary tumor sites. Our results provide the molecular basis for MSC recruitment into tumors and how this process leads to tumor metastasis.
Introduction
Tumors have long been considered as wounds that do not heal 1 . Wound healing normally requires the participation of many different cell types as well as the activation of a vast number of cellular processes including matrix degradation, proliferation, and recruitment of inflammatory cells. In addition, cells such as fibroblasts, epithelial and endothelial cells are also recruited and they too must coordinate their activities with inflammatory cells to pattern regeneration of normal tissues. As in normal wound healing, tumors also activate the recruitment of host cells into tumor beds to regulate survival and proliferation 2 . In this context recent attention has focused on the roles of dendritic, tumor associated macrophages and other early hematopoietic lineage populations that establish niches within tumors that foster and protect cancer stem cells from cytotoxic and metabolic stresses 3 . Moreover, many of these same cell populations are thought to promote and establish premetastatic niches at distant sites which ultimately facilitate the ability of disseminated tumor cells to establish metastatic foci 4, 5 .
MSCs are multipotent cells that contribute to tissue homeostasis and regeneration. Normally, MSCs are rapidly recruited into sites of injury and inflammation where they differentiate into a variety of connective tissue cell types 6, 7 . Recently, marrow-derived MSCs were shown to participate in tumor progression by establishing a favorable tumor microenvironment, differentiating into cancer-associated fibroblasts (CAFs) which establish cytokine networks that promote progression and migration [8] [9] [10] [11] [12] [13] [14] . Precisely how MSCs are recruited into primary tumor sites, how they contribute to the development of tumor niches for cancer stem cells, what regulates the conversion of MSCs into CAFs, and how CAFs promote metastasis is not entirely understood.
Skeletal metastases are one of the most serious complications of prostate cancer 15 . Growing evidence suggests that the CXC chemokine ligand 16 (CXCL16) and its receptor CXCR6 play important roles in tumor progression and bone metastasis [16] [17] [18] [19] . CXCL16 is one of a small number of chemokines expressed as both soluble and cell surface molecules and it functions as a chemoattractant for many cell types 20 . CXCL16 is secreted by cells in response to IFN-γ, TNF-α and IL-1β [21] [22] [23] [24] [25] [26] [27] [28] . CXCL16 is the sole ligand for CXCR6, a member of the seven transmembrane G protein-coupled receptor family which signals through the AKT/mTOR pathways 17 . Our group has shown that in primary and metastatic prostate cancer, CXCL16 is highly expressed compared to normal prostate epithelial cells 17, 29 . In addition, CXCL16/CXCR6 is involved in prostate cancer migration and invasion 17, 20, 25, 29 .
In the present study we demonstrate that tumor growth is dependent on the recruitment of MSCs into human and mouse prostate cancer in response to CXCL16. Once in the tumor, CXCL16 binding to CXCR6 expressed by MSCs, stimulates their conversion into CAFs, which subsequently secrete enhanced levels of CXCL12. CXCL12 expression by CAFs promotes an epithelial to mesenchymal transition (EMT) of the cancer cells, which supports metastasis to secondary sites. Together, these studies provide the molecular basis for MSC recruitment into primary tumors, and the conversion of MSCs into CAFs that ultimately lay the foundations for the EMT required establishing distant metastasis.
Results

CXCL16 secreted by prostate cancer recruits MSCs
We reasoned that cells with stem cell-like properties must rapidly migrate into wounds to initiate tissue regeneration. We hypothesized that CXCR6-expressing MSCs from the bone marrow are likely rapidly recruited into tumors in response to CXCL16. Therefore, human and mouse bone marrow MSCs ( Supplementary Fig. S1a ) were evaluated for CXCR6 expression. Human (Fig. 1a,b) and freshly isolated non-passaged (P 0 ) murine MSCs (Lin − Sca-1 + CD45 − or very small embryonic-like (VSEL) stem cells) 7, 30, 31 and second passage MSCs (P 2 ) expressed CXCR6, while MSCs isolated from CXCR6 −/− (MSC CXCR6−/− ) mice did not (Fig. 1c,d ). Tissue microarrays (TMAs) from prostate cancer patients demonstrated that CXCL16 expression correlated with tumor aggressiveness ( Fig.  1e; Supplementary Fig. S1b ). Prostate cancer and breast cancer cell lines expressed significant levels of CXCL16 ( Fig. 1f,g; Supplementary Fig. S1c-g ). In vitro, P 0 or P 2 MSCs isolated from CXCR6 wild-type mice (MSC CXCR6+/+ ) migrated toward CXCL16, while MSC CXCR6−/− did not (Fig. 1h) . To determine what role CXCL16 has in recruiting MSCs into tumors, prostate cancer was implanted s.c. into CXCR6 +/+ or CXCR6 −/− mice ( Supplementary Fig. S1h ). Significantly greater tumor volume was observed when the tumors were grown in CXCR6 +/+ vs. CXCR6 −/− mice suggesting that CXCR6 expressing host cells modulate tumor growth (Fig. 1i) . Surprisingly, more MSCs were found in the tumors grown in the CXCR6 +/+ mice than in the tumors grown in CXCR6 −/− mice ( Fig. 1j ; Supplementary Table S1) though there were no differences in MSC numbers in the marrow of the CXCR6 +/+ vs. CXCR6 −/− mice ( Supplementary Fig. S1i ), suggesting a specific recruitment of MSCs into tumors facilitates growth. To validate that these results were representative of other tumors and not specific to subcutaneous tumor growth, the studies were repeated with human prostate cancer and breast cancer cell lines in an orthotopic setting. As seen previously, robust MSC recruitment into the tumors occurred when prostate cancer or breast cancer cell lines were implanted in an orthotopic setting (Supplementary Fig. S1j-r (Fig. 2m,n) , which was regulated through Erk and NF-κB signaling ( Supplementary Fig. S2f-h ).
Knockdown of CXCL16 reduces MSC recruitment and CAF formation
To further explore the role of CXCL16 secreted by tumor cells and MSC cell recruitment, lentiviral vectors were used to silence CXCL16 expression in RM1 cells (RM1 shCXCL16 ). After clonal selection, individual clones were pooled and assayed by qRT-PCR and ELISA for the reduction of CXCL16 expression (Fig. 3a,b) . We then tested whether RM1 shCXCL16 cells have the same capabilities to stimulate migration of MSCs compared to control (RM1 Control ) cells. As expected, the knocked-down of CXCL16 expression in RM1 cells inhibited the migration of MSC cells in vitro (Fig. 3c ). In conjunction with these studies, tumor growth over time was evaluated in CXCR6 +/+ mice (Fig. 3d ). As shown in Fig. 3e , tumors generated from the RM1 Control cells rapidly developed, while tumor growth of the RM1 shCXCL16 cells was dramatically suppressed. Importantly, more MSCs were identified in the tumors grown with RM1 Control cells than in tumors grown with RM1 shCXCL16 cells ( Fig. 3f ; Supplementary Table S1 ). Taken together, the data suggest that CXCL16 expression by prostate tumors is critical for tumor growth and MSC cell recruitment. 
CAF CXCL12 promotes prostate cancer cell EMT
To explore the extent to which CXCL16 drives metastasis, we determined whether CAFderived CXCL12 activates an EMT in prostate cancer cells ( Supplementary Fig. S4a ). Loss of cell-cell contacts and the emergence of a spindle-shaped morphology was observed following CXCL12 treatments of prostate cancer cells or when they were cocultured with MSCs CXCR6+/+ , but not when cocultered with MSC CXCR6−/− (Fig. 4a) . In fact, when prostate cancer cells were treated with CXCL12 or cocultured with MSCs CXCR6+/+ , but not MSCs CXCR6−/− cells, a near complete loss of the epithelial transcriptome occurred including E-cadherin, reduced cytokeratin, enhanced expression of N-cadherin, vimentin, α-SMA, β-catenin, snail, and slug were observed ( Fig. 4a-c) . When tumor microarrays were stained for E-cadherin or N-cadherin, more E-cadherin expressing prostate cancer cells were detected in the benign prostate tissues, whereas more N-cadherin expressing prostate cancer cells were detected in the Gleason 4+5 prostate cancers ( [36] [37] [38] . Enhanced expression of the CXCL12 receptor CXCR4 is known to facilitate migration and metastasis in vivo 39, 40 . We observed that CXCR4 expression by prostate cancer was enhanced following induction of an EMT phenotype in vitro and was associated with enhanced tumor growth in vivo (Fig. 4f,g ). Studies with anti-CXCR4 antibody and the CXCR4 inhibitor AMD3100 showed that CXCL12 induces prostate cancer towards an EMT phenotype ( Fig. 4h; Supplementary Fig. S4c-e) . In fact, prostate cancer cells which had undergone an EMT were significantly more responsive than their parental counterparts to CXCL12 or serum (Fig. 5a ). Such that CXCR4 blockade prevented prostate cancer migration in vitro (Fig. 5b) .
EMT-induced CXCR4 expression promotes metastasis
In an animal model of bone metastasis, RFP expressing wild-type (RM1 WT ) or EMT induced RM1 cells (RM1 EMT ) ( Supplementary Fig. S5a ) were incubated with AMD3100 or vehicle in vitro, and then injected by an intra-cardiac (i.c.) route into CXCR6 +/+ or CXCR6 −/− mice to establish prostate cancer bone metastases ( Supplementary Fig. S5b ). First, we examined CXCL12 levels in a number of osseous sites and in blood ( Supplementary Fig. S5c ). All the animals from CXCR6 +/+ or CXCR6 −/− mice had significant numbers of disseminated tumor cells (DTCs) in their bones 10 days following injection of RM1 WT or RM1 EMT cells (Fig. 5c-h ). In contrast, RM1 WT cells pretreated with AMD3100 had a reduced number of disseminated tumor cells (DTCs) in their calvaria, spine, and femur from CXCR6 +/+ mice (Fig. 5c ,e,f). Strikingly, animals receiving RM1 EMT cells showed a significant increase of in the total DTC load in most osseous tissues compared to animals injected with the RM1 WT cells alone. Critically, the number of DTCs were significantly reduced following CXCR4 blockade (Fig. 5c ,e,f). However, fewer DTCs were identified in the bones of the CXCR6 −/− vs. CXCR6 +/+ mice (Fig. 5d,g,h ). Together these data suggest CXCL16 initiated induction of an EMT-and CXCR4 expression via MSC activation plays an important role and critical role in prostate cancer cell dissemination and metastasis.
Discussion
Tumors arise from cells that have sustained and multiple genetic mutations resulting in deregulation of normal growth-control mechanisms 41 . Recent evidence also suggests that the microenvironment itself regulates crucial neoplastic progression steps in hematologic tumors 42 . Cancer cells not only interact with each other, their extracellular matrix and inflammatory cells, but also with recruited and resident cells of mesenchymal origin. The characteristic transformation of stromal cells that accompanies, or precedes the malignant conversion of epithelial cells has been linked to CAFs [43] [44] [45] . Several cancer types demonstrate the concept that these fibroblasts can determine the fate of the epithelial cells, promote malignant progression either through soluble factors, and cell-cell interactions and/or alterations of the extracellular matrix 45 . The complexity of these interactions has been amplified by studies showing alterations in resident cells may be drivers in cancer progression 46 .
MSCs are multipotent cells that contribute to tissue homeostasis and regeneration. Tumors recruit MSCs to facilitate tumor progression and metastasis. Here, we provide evidence that the recruitment of MSCs into prostate cancer is dependent on the expression of the CXCR6 ligand, CXCL16 by tumor cells (Fig. 6 ). CXCR6 signaling supports the recruitment, conversion and activation of MSC into CXCL12 secreting CAFs. Moreover, enhanced CXCL12 secretion supports an EMT conversion of the prostate cancer cells and an increase in the expression of the CXCL12 receptor, CXCR4. These events result in enhanced tumor progression and ultimately extravasation and metastasis. Targeting MSCs and the CXCL16/ CXCR6 axis may prevent tumor progression and metastasis of prostate cancer and provide a more effective therapeutic strategy for prostate cancer.
Several lines of evidence demonstrate that cells with stem cell-like properties must be able to migrate into wound sites rapidly in order for regeneration to occur [47] [48] [49] [50] . In the context of neoplasia, bone marrow derived MSCs have been shown to increase the metastatic potential of weakly metastatic human breast cancer cells, in part through the conversion to a CAF phenotype 51 . We demonstrate that primary small Lin − Sca-1 + CD45 − cells (VSEL stem cells) isolated from marrow and MSCs passaged in vitro express high mRNA levels of CXCR6 and migrate towards CXCL16. CXCL16 exists both in soluble and transmembrane forms 52 . CXCL16 is expressed on monocytes, macrophages, B cells, and dendritic cells 53, 54 and both forms of CXCL16 are expressed by human tumor cells 16, 17, 55, 56 . The precise role of soluble vs. transmembrane CXCL16 in tumor progression remains unclear. Transmembrane CXCL16 may function to suppress tumor proliferation, while soluble CXCL16 induces proliferation and migration of cancer cells 20 . Which form of CXCL16 regulates prostate cancer growth within tumors is still unclear.
Previous work by our group demonstrated that CXCR6 expression in tumors correlated with Gleason score. Using lentiviral vectors to overexpress CXCR6 in PC3, LNCaP C4-2B, and LNCaP cells, or by reducing CXCR6 expression by siRNA, we also found that modifying CXCR6 expression altered the ability of prostate cancer cell lines to invade and grow both in vitro and in vivo 17 . In addition, CXCR6 regulates the expression of several proangiogenic factors including IL-8 and vascular endothelial growth factor (VEGF), both of which are likely to participate in the regulation of tumor angiogenesis 17 . In part, binding of CXCL16 to CXCR6 induces activation of Akt, p70S6K, and eukaryotic initiation factor 4E binding protein 1 in prostate cancer cells in addition to mammalian target of rapamycin (mTOR) pathways 17 . Moreover, rapamycin not only drastically inhibited CXCL16-induced prostate cancer cell invasion and growth but also reduced secretion of IL-8 or VEGF levels and inhibited expression of other CXCR6 targets including CD44 and matrix metalloproteinase 17 .
The present study further adds to the complexity of CXCL16/CXCR6 signaling and the role that paracrine/autocrine loops play in tumor progression. These findings are similar to previous observations showing that CXCL12/CXCR4 signaling 57,58 supports cross-talk between CAFs and prostate cancer 59 . Our results illustrate the molecular basis for MSC recruitment into tumors and how this process leads to tumor metastasis by coupling activities of the CXCL12/CXCR4 and CXCL16/CXCR6 axes. By demonstrating that MSCs play an active role in establishing an EMT in cancer which ultimately facilitates metastasis, MSCs are critical components of the host-response network in tumors and represent viable entities for the design of targeting therapies to prevent the establishment of distant metastasis.
Methods Animals
Five to seven week-old male CXCR6 +/+ or CXCR6 −/− mice (Jackson Laboratory, Bar Harbor, ME) and SCID mice (CB.17. SCID; Taconic, Germantown, NY) were used as transplant recipients. All animal procedures were performed in compliance with the institutional ethical requirements and approved by the University of Michigan Committee for the Use and Care of Animals (UCUCA).
Cell lines
The human prostate cancer cell lines PC3, LNCaP, and DU145, and murine prostate cancer cell lines RM1 and Tramp were used (American Type Culture Collection (ATCC), Rockville, MD). C4-2B were originally isolated from a lymph node of a patient with disseminated bony and lymph node involvement. Prostate cancer cell lines were cultured in RPMI 1640 (Invitrogen, Grand Island, NY) with 10% fetal bovine serum (FBS, Invitrogen), 1% penicillin-streptomycin (P/S, Invitrogen). The human prostate epithelial cell line RWPE-1 (ATCC) was cultured in Keratinocyte-SFM with supplements (Invitrogen). The mouse prostate epithelial cell line NMPE (CHI Scientific, Maynard, MA) was cultured in Mouse Prostate PrimaCell™ medium (CHI Scientific). The human breast epithelial cell line MCF-10A and breast cancer cell line MCF-7 were kindly provided by Dr. Max Wicha (University of Michigan). MCF-10A cell line was cultured in DMEM/F12 with supplements (Invitrogen) and MCF-7 cell line was cultured in DMEM with supplements (Invitrogen). Conditioned media were collected and frozen after filtration through a 0.22 μm filter. For induction of EMT, RM1 cells were cultured to confluence, and serum-starved for 24 hours. The cells were cultured in RPMI with 0.1% FBS supplemented with 200 ng/ml CXCL12 (cat. 350-NS, R&D Systems, Minneapolis, MN) for 48 hours, and termed RM1 EMT vs.
RM1 WT . RM1 cells used in metastasis assays were labeled with red fluorescent protein (RFP) by lentiviral transfection (Supplementary Fig. S5a ) and selected by FACS.
MSC cells
Human MSCs (hMSCs, Lonza, Walkersville, MD), and freshly isolated mouse MSC cells (non-passaged (P 0)) ( Lin − Sca-1 + CD45 − cells or very small embryonic-like (VSEL) stem cells) and primary bone marrow derived-MSC cells (passaged once (P 1 ) or twice (P 2 )) from CXCR6 +/+ or CXCR6 −/− mice were used for this study. The hMSC cells were cultured in DMEM supplemented with 10% FBS, and 1% P/S. For mouse MSCs, after sacrifice, marrow was flushed from femurs and tibias of both CXCR6 +/+ and CXCR6 −/− mice into α-MEM (Invitrogen) with 2% FBS, to generate primary MSC cells and cultured in α-MEM containing 10% FBS and 1% P/S. Once confluent, the cells were passaged 2-3 times to minimize macrophage contamination. Subsequently, repopulated bone marrow derivedMSCs were obtained, and cells were cultured in DMEM containing 10% FBS and 1% P/S. For MSC differentiation assays, mouse primary bone marrow derived-MSC cells were cultured in adipogenic, osteogenic, or chondrogenic conditions for 2 weeks, and cells were stained with Alizarin Red S, Oil Red O, and Alcian Blue, respectively.
Isolation of MSC P0 (VSEL) cells
Small 
Western blot analyses
Cells were lysed in RIPA buffer with protease inhibitors and lysates separated on 10% SDSpolyacrylamide gel and transferred to PVDF membranes. 
Immunohistochemistry
Cells were fixed and tissue sections were de-waxed and re-hydrated, then blocked with Image-iT FX signal enhancer for 30 min, and incubated 2 hours at room temperature in dark with 10 μg/ml primary antibodies combined with reagents of Zenon Alexa Fluor 488 (green) or 555 (red) labeling kit. CXCR6 (cat. NLS-1102, 1:100 dilution, Novus Biologicals, Littleton, CO), fibroblast-specific protein 1 (FSP1, cat. 07-2274, 1:100 dilution, Millipore, Temecula, CA), CXCL12 (cat. Table S1 ). Tumors were also established by injecting RM1 Control or RM1 shCXCL16 (1 × 10 4 ) cells in growth factorreduced Matrigel s.c. into 5-7 week-old male CXCR6 +/+ mice ( Fig. 3d ; Supplementary  Table S1 ). In some cases, tumors were also established by injecting human PC3 cells (2×10 5 ) mixed with MSC P0 CXCR6+/+ or MSC P0 CXCR6−/− cells (2×10 3 ) in growth factorreduced Matrigel s.c. into 5-7 week-old male SCID mice. The animals were monitored daily and tumor volumes were evaluated every 3-7 days. Tumor volumes were calculated using the formula V= (the shortest diameter) × (the longest diameter) × height. After 23-42 days the animals were sacrificed. The tumors were measured and prepared for Lin − Sca-1 + CD45 − cell analyses and histology.
Orthotopic tumor growth
After anesthesia with 2-4% isoflurane inhalation, a low midline incision was made in the lower abdomen. The human and murine prostate cancer cells (5×10 4 -5×10 5 ) in 20 μl of PBS were injected into the right or left dorsolateral lobe of the prostate of 5-7 week-old male SCID or CXCR6 +/+ mice, and the wound was closed with surgical clips. The human breast cell lines (1×10 6 ) in growth factor-reduced Matrigel were injected abdominal fat pad of 5-7 week-old female SCID mice (Supplementary Fig. S1j ; Supplementary Table S1 ).
In vivo metastasis assays
Cells (2×10 5 RFP labeled RM1 cells/mouse) were incubated with 10 μM AMD3100 (cat. A5602, Sigma) or vehicle for 30 min at 4°C, and then introduced into 5-7 week-old male CXCR6 +/+ or CXCR6 −/− mice by intra-cardiac (i.c.) injection. qPCR and immunohistochemistry were used to identify the location of the cells. Metastasis was first assessed in osseous tissues and blood samples at day 10 by qPCR using a probe for the red fluorescent protein gene [AICSVE0-F AGAGCATCTACATGGCCAAGAAG (forward), AICSVE0-R TCGTTGTGGCTGGTGATGTC (reverse), and FAM CTTGCTGTCCACGTAGTAGT (TaqMan probe; Applied Biosystems)]. The data were normalized to mouse tissue β-actin (Mm00607939_s1). Immunohistochemistry for prostate cancer cells in the marrow was also used for metastasis assays. The numbers of RM1 cells were quantified on the endosteal region of the 7 long bones defined as 10 cell diameters from the bone surfaces.
Statistical analyses
All in vitro experiments were performed at least three times with similar results and representative assays are shown. Statistical analysis was performed by ANOVA or Student's t-test using GraphPad Instat (GraphPad, San Diego, CA) with significance at P<0.05.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material. Model showing putative potential mechanisms underlying primary prostate cancer progression by the recruitment of mescenchymal cells (MSCs) and bone metastasis. Secretion of CXCL16 by cancer cells recruits MSCs into tumor sites. Tumor-derived CXCL16 interacts with its receptor, CXCR6 on MSCs and activates signal transduction, leading MSCs to convert into cancer-associated fibroblasts (CAFs), which secrete the high levels of CXCL12. CXCL12 promotes the malignant transformation of proliferating cancer cells to an epithelial-mesenchymal transition (EMT). EMT enhances CXCR4 expression in prostate cancer cells. CXCR4 expression facilitates metastasis.
